TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,199,043 | -42.3% | 245,978 | -0.9% | 0.00% | -100.0% |
| Q2 2023 | $3,811,523 | -21.8% | 248,146 | +14.5% | 0.00% | 0.0% |
| Q1 2023 | $4,875,135 | +8.7% | 216,769 | +1.7% | 0.00% | 0.0% |
| Q4 2022 | $4,484,080 | -15.0% | 213,223 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $5,276,000 | +14.3% | 214,118 | +12.4% | 0.00% | 0.0% |
| Q2 2022 | $4,615,000 | -18.9% | 190,501 | -13.7% | 0.00% | 0.0% |
| Q1 2022 | $5,689,000 | -17.5% | 220,787 | -0.6% | 0.00% | 0.0% |
| Q4 2021 | $6,894,000 | +27.4% | 222,088 | -0.5% | 0.00% | 0.0% |
| Q3 2021 | $5,413,000 | +82.3% | 223,250 | +9.7% | 0.00% | 0.0% |
| Q2 2021 | $2,969,000 | -42.4% | 203,454 | -1.4% | 0.00% | 0.0% |
| Q1 2021 | $5,154,000 | -3.4% | 206,412 | +5.5% | 0.00% | 0.0% |
| Q4 2020 | $5,334,000 | – | 195,689 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |